AR130808A1 - 1,3,5-triazinas 2,4,6-trisustituidas como moduladores de cx3cr1 - Google Patents

1,3,5-triazinas 2,4,6-trisustituidas como moduladores de cx3cr1

Info

Publication number
AR130808A1
AR130808A1 ARP230102794A ARP230102794A AR130808A1 AR 130808 A1 AR130808 A1 AR 130808A1 AR P230102794 A ARP230102794 A AR P230102794A AR P230102794 A ARP230102794 A AR P230102794A AR 130808 A1 AR130808 A1 AR 130808A1
Authority
AR
Argentina
Prior art keywords
alkyl
heart failure
haloalkyl
hydroxy
optionally substituted
Prior art date
Application number
ARP230102794A
Other languages
English (en)
Inventor
Karolina Nilsson
Martin Bauer
Maria Olwegard-Halvarsson
Mikael Brink
Jon Paul Janet
Frederick Bergstrm
Mateusz Plesniak
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR130808A1 publication Critical patent/AR130808A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se desvelan ciertos compuestos de 1,3,5-triazina 2,4,6-trisustituida de fórmula (1), y sales farmacéuticamente aceptable de las mismas, junto con composiciones que las contienen y su uso en terapia. Los compuestos son moduladores de CX₃CR1 y de ese modo son particularmente útiles en el tratamiento o la profilaxis de trastornos cardiovasculares tales como miocardiopatía dilatada no isquémica e insuficiencia cardíaca. Reivindicación 1: Compuesto de fórmula (1) en donde R¹ es un alquilo C₃₋₆ ramificado o haloalquilo C₃₋₆ ramificado; R² es un alquilo C₁₋₃ o haloalquilo C₁₋₃; m es 1 o 2; R³ y R⁴ se seleccionan independientemente de H, halógeno, alquilo C₁₋₃ y haloalquilo C₁₋₃; A es fenilo, heteroarilo monocíclico, arilo bicíclico o heteroarilo bicíclico; p es 0, 1, 2, 3 o 4; cada R⁵ se selecciona independientemente entre halógeno, hidroxi, oxo, alquilo C₁₋₃, haloalquilo C₁₋₃, alcoxi C₁₋₄, haloalcoxi C₁₋₄, alcoxi C₁₋₄-alquilo C₁₋₃, hidroxialquilo C₁₋₃, -CN, -(CH₂)qCN, -C(O)NR⁶R⁷, -NS(O)R⁶R⁷, -(CH₂)qR⁸, -C(O)R⁸, -C(O)OR⁹, -OC(O)R⁹, -NR⁶C(O)R⁷, -NR⁶R⁷, cicloalquilo C₃₋₆, heteroarilo de 4 - 6 miembros, heterociclilo de 4 - 6 miembros y fenilo, en donde el cicloalquilo C₃₋₆ o heterociclilo de 4 - 6 miembros puede estar opcionalmente sustituido con 1 a 3 sustituyentes seleccionados entre hidroxi, oxi, halógeno y -C(O)OR⁹, el heteroarilo de 4 - 6 miembros puede estar opcionalmente sustituido con 1 a 3 sustituyentes halógeno, el alcoxi C₁₋₄ puede estar opcionalmente sustituido con un heterociclilo de 4 - 6 miembros, cada R⁶ y R⁷ se seleccionan independientemente de H y alquilo C₁₋₃, cada q es independientemente 1, 2 o 3, cada R⁸ es independientemente un heterociclilo de 4 - 6 miembros, en donde el heterociclilo está opcionalmente sustituido con un oxi, y cada R⁹ es independientemente un alquilo C₁₋₅; o una sal farmacéuticamente aceptable o tautómero del mismo. Reivindicación 45: El compuesto de la reivindicación 1, seleccionado de entre: N-(4-(-2-(4-Cianofenil)propil)-6-(((R)-1-hidroxi-4-metilpentan-2-il)amino)-1,3,5-triazin-2-il)metanosulfonamida, N-(4-(2-(4-clorofenil)propil)-6-(((R)-1-hidroxi-4-metilpentan-2-il)amino)-1,3,5-triazin-2-il)metanosulfonamida, y sales y tautómeros farmacéuticamente aceptables del mismo. Reivindicación 47: Un compuesto de cualquiera de las reivindicaciones 1 - 45, o una sal farmacéuticamente aceptable o tautómero del mismo, para su uso en el tratamiento de enfermedades cardiovasculares. Reivindicación 48: El compuesto de la reivindicación 47 en donde la enfermedad cardiovascular es miocardiopatía dilatada no isquémica, insuficiencia cardíaca, enfermedad cardiovascular asociada con afecciones autoinmunes, enfermedad cardiovascular asociada con enfermedades inflamatorias crónicas, insuficiencia cardíaca con fracción de eyección reducida, insuficiencia cardíaca con fracción de eyección levemente reducida, o insuficiencia cardíaca con fracción de eyección conservada.
ARP230102794A 2022-10-19 2023-10-19 1,3,5-triazinas 2,4,6-trisustituidas como moduladores de cx3cr1 AR130808A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263417472P 2022-10-19 2022-10-19

Publications (1)

Publication Number Publication Date
AR130808A1 true AR130808A1 (es) 2025-01-22

Family

ID=88511235

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102794A AR130808A1 (es) 2022-10-19 2023-10-19 1,3,5-triazinas 2,4,6-trisustituidas como moduladores de cx3cr1

Country Status (17)

Country Link
US (2) US20240199558A1 (es)
EP (1) EP4605388A1 (es)
JP (1) JP2025537492A (es)
KR (1) KR20250086780A (es)
CN (1) CN120077035A (es)
AR (1) AR130808A1 (es)
AU (1) AU2023362450A1 (es)
CL (1) CL2025001155A1 (es)
CO (1) CO2025006339A2 (es)
CR (1) CR20250196A (es)
DO (1) DOP2025000096A (es)
IL (1) IL320305A (es)
MX (1) MX2025004633A (es)
PE (1) PE20251587A1 (es)
TW (1) TW202430188A (es)
UY (1) UY40495A (es)
WO (1) WO2024083933A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20251587A1 (es) * 2022-10-19 2025-06-16 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1
WO2025219939A1 (en) * 2024-04-17 2025-10-23 Astrazeneca Ab Salts and polymorphs of cx3cr1 modulators
WO2025219950A1 (en) * 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19960683A1 (de) * 1999-12-15 2001-08-23 Aventis Cropscience Gmbh Substituierte 2,4-Diamino-1,3,5-triazine, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
WO2005033115A1 (en) 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
GB0401269D0 (en) 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
CN101522693B (zh) 2006-09-29 2012-01-04 阿斯利康(瑞典)有限公司 5,7-二取代的[1,3]噻唑并[4,5-d]嘧啶-2(3h)-胺衍生物和它们在治疗中的用途
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
AR071036A1 (es) 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
EA201591291A1 (ru) 2013-01-08 2015-12-30 Савира Фармасьютикалз Гмбх Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
PE20251587A1 (es) * 2022-10-19 2025-06-16 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1

Also Published As

Publication number Publication date
US20240199558A1 (en) 2024-06-20
UY40495A (es) 2024-05-15
AU2023362450A1 (en) 2025-05-29
IL320305A (en) 2025-06-01
US20240383866A1 (en) 2024-11-21
DOP2025000096A (es) 2025-07-15
TW202430188A (zh) 2024-08-01
US12404253B2 (en) 2025-09-02
CN120077035A (zh) 2025-05-30
CL2025001155A1 (es) 2025-08-29
CR20250196A (es) 2025-11-21
EP4605388A1 (en) 2025-08-27
WO2024083933A1 (en) 2024-04-25
PE20251587A1 (es) 2025-06-16
KR20250086780A (ko) 2025-06-13
MX2025004633A (es) 2025-06-02
JP2025537492A (ja) 2025-11-18
CO2025006339A2 (es) 2025-05-29

Similar Documents

Publication Publication Date Title
AR120338A1 (es) Piridazinonas como inhibidores de parp7
PE20220133A1 (es) Inhibidores del inflamasoma nlrp3
AR116978A1 (es) Fungicidas de tolilo sustituido
AR116913A1 (es) Inhibidores de apol1 y sus métodos de uso
AR119971A1 (es) Derivados de piridazin-3(2h)-ona fusionados con azol
RU2018140092A (ru) Новые пиразолпиримидиновые производные
AR124193A1 (es) Compuestos moduladores de rxfp1
AR094148A1 (es) Dihidropiridopirazinonas inhibidoras de la proteina bet
AR108906A1 (es) Heterociclos de biarilmetilo
AR091208A1 (es) Derivados de piperidina
AR120377A1 (es) Derivados heteroaromáticos de sulfiliminas o sulfoximinas con actividad fungicida
AR115906A1 (es) Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas
AR120556A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
AR127277A1 (es) Composiciones y métodos para modular la formación de inclusión y gránulos de estrés
AR116302A1 (es) Pirazoles fungicidas sustituidos con nitroanilino
AR117228A1 (es) DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS
AR126048A1 (es) Derivados heterocíclicos condensados
PE20240634A1 (es) Compuestos triciclicos y usos de los mismos
AR128112A1 (es) Compuesto, antagonista del receptor de angiotensina ii tipo 1 y composición farmacéutica
PE20221454A1 (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4
AR119980A1 (es) Composiciones nematicidas
AR093763A1 (es) Antagonistas de ccr3 de arilsulfonamida isotopicamente enriquecidas
AR131059A1 (es) Derivados microbicidas de tetrahidroisoquinolina
AR129683A1 (es) Compuestos herbicidas que contienen imidazol
AR126178A1 (es) Compuesto, antagonista del receptor de endotelina a y composición farmacéutica